Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 14.50 | 5.69% | 0.78 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Stochastic Sell Signal | Bearish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 16 hours ago |
| 1.5x Volume Pace | about 20 hours ago |
| Up 2 ATRs | about 20 hours ago |
| Up 10% | about 20 hours ago |
| Up 5% | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 02/28/2024
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.33 |
| 52 Week Low | 9.0 |
| Average Volume | 134,447 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 13.81 |
| 20-Day Moving Average | 12.60 |
| 10-Day Moving Average | 12.96 |
| Average True Range | 1.04 |
| RSI (14) | 63.64 |
| ADX | 18.89 |
| +DI | 38.10 |
| -DI | 10.99 |
| Chandelier Exit (Long, 3 ATRs) | 13.68 |
| Chandelier Exit (Short, 3 ATRs) | 14.68 |
| Upper Bollinger Bands | 13.85 |
| Lower Bollinger Band | 11.35 |
| Percent B (%b) | 1.26 |
| BandWidth | 19.87 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.34 |
| MACD Histogram | 0.3127 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.53 | ||||
| Resistance 3 (R3) | 19.73 | 18.26 | 18.69 | ||
| Resistance 2 (R2) | 18.26 | 16.98 | 18.16 | 18.41 | |
| Resistance 1 (R1) | 16.38 | 16.19 | 17.32 | 16.18 | 18.13 |
| Pivot Point | 14.91 | 14.91 | 15.38 | 14.81 | 14.91 |
| Support 1 (S1) | 13.03 | 13.63 | 13.97 | 12.83 | 10.87 |
| Support 2 (S2) | 11.56 | 12.84 | 11.46 | 10.59 | |
| Support 3 (S3) | 9.68 | 11.56 | 10.31 | ||
| Support 4 (S4) | 9.48 |
